These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 16716134

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
    Digumarti R, Sinha S, Nirni SS, Patil SG, Pedapenki RM.
    Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
    [Abstract] [Full Text] [Related]

  • 24. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A.
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [Abstract] [Full Text] [Related]

  • 25. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS.
    Blood; 2001 May 15; 97(10):2998-3003. PubMed ID: 11342423
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G, Seth T, Garg V, Juneja R, Mahapatra M, Datta SK, Upadhyay AD, Saxena R.
    Clin Lymphoma Myeloma Leuk; 2021 Jan 15; 21(1):e99-e104. PubMed ID: 33039358
    [Abstract] [Full Text] [Related]

  • 27. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G, Giordano M, Malaguarnera M.
    Expert Rev Hematol; 2012 Feb 15; 5(1):27-38. PubMed ID: 22272702
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
    Bessmertny O, Robitaille LM, Cairo MS.
    Curr Pharm Des; 2005 Feb 15; 11(32):4177-85. PubMed ID: 16375739
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Rasburicase dose optimization for tumor lysis syndrome management in a network of community oncology practices.
    Gilmore S, Carroll M, Koselke E, Hough S.
    J Oncol Pharm Pract; 2024 Jul 15; 30(5):867-872. PubMed ID: 37563922
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
    Eng S, Lee CS, Ahn S, Sharma A.
    J Oncol Pharm Pract; 2020 Mar 15; 26(2):338-344. PubMed ID: 31088218
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR, Burry LD, Cheng DK.
    Pharmacotherapy; 2007 Jan 15; 27(1):111-21. PubMed ID: 17192165
    [Abstract] [Full Text] [Related]

  • 38. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
    Bertrand Y, Mechinaud F, Brethon B, Mialou V, Auvrignon A, Nelken B, Notz-Carrère A, Plantaz D, Patte C, Urbieta M, Baruchel A, Leverger G, SFCE.
    J Pediatr Hematol Oncol; 2008 Apr 15; 30(4):267-71. PubMed ID: 18391694
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S, Han Y, Zhang W, Zhang T, Yao X, Liu L.
    J Med Econ; 2019 Aug 15; 22(8):742-750. PubMed ID: 30939962
    [Abstract] [Full Text] [Related]

  • 40. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK, Chiang AK, Chan GC, Ha SY.
    Cochrane Database Syst Rev; 2017 Mar 08; 3(3):CD006945. PubMed ID: 28272834
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.